US 8426450

I'll search for authoritative information on US 8426450, including USPTO records and any CAFC 2026 docket activity.

Let me pull the actual claim text and check for any Helsinn-related 2026 Federal Circuit activity.

US 8,426,450 B1 — Summary

Caveat on method and dates: I do not have direct authenticated access to the USPTO PatentCenter/Global Dossier database or the CAFC docket system; the following is based on web-search results (Google Patents, FreePatentsOnline, PubChem/NCBI patent record, FDA Orange Book excerpts, and litigation-aggregator data), the authoritative full patent text you supplied, and PTAB/court documents surfaced in search. Also note a date discrepancy in the prompts: the system clock reads 2026-09-19, while your instruction states April 26, 2026. This affects only the framing of "2026 CAFC dockets," not the patent facts.

Bibliographic data

Abstract

"Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor. The compounds have the general formula (I)…"

Plain-language overview (description-based, not verbatim claims)

• Field/subject matter: Substituted 4-phenyl-pyridine (netupitant-family) compounds, their pharmaceutically acceptable salts/adducts, pharmaceutical compositions, and methods of treating NK1-receptor-mediated disease (nausea/vomiting, bladder dysfunction, depression, anxiety).
• Chemistry platform: The disclosure centers on a Markush genus of formula (I) with variables R, R₁–R₆, X (e.g., —NR¹⁰¹C(O)), Y (e.g., heterocycloalkyl/heterocycloalkylalkyl), Z (including N-oxide variants), and a proviso that if a non-pyridine N-oxide is present, then more than one N-oxide must be present (the specification also states an embodiment that "excludes all N-oxide forms"). The specification names eight worked compounds GA1–GA8, including GA1 = fosnetupitant (the 1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium phosphonooxymethyl derivative of netupitant).
• Independent-claim structure (as best I can determine): Third-party examination citations (e.g., the WO 2017/211663 search report) list US 8,426,450 as relevant to claims 1–20 and specifically cite claim 1 plus the paragraphs later appearing around columns 17–21 and 39–41 (the compound genus/utility and work-up/PK sections). Consistent with the disclosure, the independent claims cover: (1) a compound / genus claim — a substituted 4-phenyl-pyridine of formula (I) (or pharmaceutically acceptable salt/adduct); and (2) additional independent claims directed to a pharmaceutical composition and to a method of treating an NK1-mediated disease (e.g., emesis/CINV) by administering a compound of formula (I). An FDA Orange Book listing as both "drug substance" and "drug product" is consistent with a compound claim plus a composition claim.
• Uncertainty flagged: I could not retrieve the issued US claim text verbatim in this session. The exact wording, the precise independent-claim count (compound/composition/method), and whether the issued genus was narrowed to specific species are not confirmed to a high degree of confidence. Treat the claim characterization above as directionally correct but subject to verification against the printed patent.

Litigation / CAFC — specifically for '450

• District court: Helsinn Healthcare SA v. Gland Pharma Ltd — D.N.J. case Nos. 3:22-cv-04635 and 2:22-cv-04635 (filed 2022), a Paragraph IV/ANDA action asserting a patent family that includes US 8,426,450 among several patents (other asserted numbers include 9,908,907; 9,403,772; 10,624,911; 10,828,297; 8,895,586; 11,312,698; 10,208,073; 10,717,721; 9,186,357). (Sources: Unified Patents litigation portal, IPWatchdog "Patent Filings Roundup" 2022.)
• PTAB (related, not necessarily '450): IPR2025-00945, Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. — surfaced in dockets, but the excerpts show claim terms ("complete response," "independently effective") and a " '297 patent" consistent with a different Helsinn patent, not '450.
• CAFC 2026 dockets: I found no CAFC 2026 appeal involving US 8,426,450 in the search results returned. Federal Circuit 2026 activity surfaced in my searches (e.g., Fed. Express v. Qualcomm, Ironburg v. Valve, Enviro Tech v. Safe Foods) is unrelated to '450. I cannot rule out a docket I did not surface, and I am not asserting with certainty that none exists.

Related family (for context, not a substitute for '450)

The '450 is the US parent of a family that includes US 8,895,586 (methods of treating emesis), 9,403,772, 9,908,907, 10,208,073, 10,717,721, 11,312,698, and pending US 2022/0401463; the international counterpart is WO 2013/082102 A1 and EP 2785706 B1. The active pharmaceutical ingredient fosnetupitant (GA1) is marketed in Akynzeo (IV).

I'll research litigation involving US patent 8426450. Let me run several targeted searches.

Let me dig deeper into the specific cases and check for others.

Let me verify whether any other cases or PTAB challenges involve the '450 patent specifically.

Litigation Involving U.S. Patent No. 8,426,450

Patent identified literally as: US 8,426,450 — "Substituted 4-phenyl pyridines having anti-emetic effect," filed May 23, 2012, issued April 23, 2013, assignee Helsinn Healthcare SA. It is an Orange Book–listed patent for AKYNZEO (NDA 210493, product 002 — fosnetupitant chloride hydrochloride / palonosetron hydrochloride solution, IV), with an Orange Book expiration date of May 23, 2032 (listed as drug substance and drug product). Source: https://patents.google.com/patent/US8426450/en and https://www.drugpatentwatch.com/p/patent/8426450

Known litigation

I found one litigation — a Hatch-Waxman (ANDA/Paragraph IV) action that was filed as two docket listings:

Nature of the case: Helsinn sued after receiving Gland's June 2, 2022 and July 11, 2022 Paragraph IV notice letters in which Gland certified that the claims of the '450 patent (among others) were invalid, unenforceable, and/or not infringed. Gland counterclaimed for declaratory judgments of invalidity and non-infringement of the '450 patent, asserting § 103 obviousness over, inter alia, U.S. 6,479,483 ("Bös"), WO 99/33846, DeGoey, U.S. 7,211,579 ("Funk"), Krise I, and Oslob, plus indefiniteness/enablement challenges regarding the "pharmaceutically acceptable salt" limitations. (Gland's Amended Answer and Counterclaims, D.I. 25; source: https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf)

Resolution: The parties settled. Under the Consent Judgment and Dismissal Order (D.I. 50):

• Gland admitted that submission of ANDA No. 217374 was a technical act of infringement under 35 U.S.C. § 271(e)(2)(A);
• Gland did not rebut the statutory presumption that the Helsinn patents are valid and enforceable;
• Gland and its affiliates were enjoined from manufacturing, using, offering to sell, selling, or importing the generic fosnetupitant/palonosetron product covered by ANDA No. 217374 until expiry (or an earlier agreed date);
• All claims, counterclaims, and affirmative defenses were dismissed (the order text says "without prejudice"; the docket entry description recites "with prejudice" — the two are inconsistent, so I flag it rather than resolve it);
• Each party waived any right to appeal, and the court retained jurisdiction to enforce the order.

Source: https://www.courtlistener.com/docket/63601016/50/helsinn-healthcare-sa-v-gland-pharma-limited/ and https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf

Notes on the two docket numbers

The Google Patents family entry lists both 3:22-cv-04635 and 2:22-cv-04635 as "US case filed in New Jersey District Court." Unified Patents shows the same two entries with one "Open" and one "Closed." CourtListener's docket (No. 63601016) is indexed under 3:22-cv-04635, while the complaint text and Gland's counterclaims refer to "Case No. 2:22-cv-04635." These appear to be the same single action (filed in the Newark vicinage as 2:22-cv-04635 and/or renumbered 3:22-cv-04635 in Trenton), not two separate suits. I could not confirm a formal reassignment/renumbering order from the sources available.

What I did NOT find

• No other district court litigation asserting the '450 patent. DrugPatentWatch's party and drug-name searches return only this Gland Pharma case for the '450 patent.
• No CAFC appeal — both parties expressly waived appeal in the consent judgment.
• No PTAB proceeding against the '450 patent. The 2025 PTAB petitions by Azurity Pharmaceuticals (IPR2025-00945 and related) target U.S. 9,186,357; 8,623,826; 10,828,297; and 9,943,515 — not the '450 patent. (Source: https://www.drugpatentwatch.com/p/litigation/drugname/index.php?query=NETUPITANT%3b+PALONOSETRON+HYDROCHLORIDE)
• No foreign litigation involving the '450 patent family members was identified in the sources consulted.

Confidence and caveats

• This is based on public aggregators (Google Patents, Unified Patents litigation portal, DrugPatentWatch, CourtListener, paragraphfour.com) rather than a direct PACER/CAFC docket pull; I did not independently verify the current PACER docket in this session.
• The '450 patent is a drug-substance/drug-product patent, so any additional Paragraph IV challenges to the fosnetupitant IV product would be filed against Helsinn; if additional suits were filed after mid-2022 naming the '450 patent, they did not surface in my searches. I cannot rule that out with certainty.
• Counterclaim's prior-art citations and the consent-judgment terms are quoted from the documents above and are reproduced literally, including the source documents' own apparent typos (e.g., "Helsinki" for "Helsinn").

PTAB Proceedings on US 8,426,450 ("Substituted 4-phenyl pyridines having anti-emetic effect")

Prepared 2026-09-19. Source of record: USPTO Open Data Portal structured "PTAB proceedings on file" block supplied with this task, supplemented by public web research (PTAB E2E/Docket Alarm mirrors, district-court records, FDA Orange Book).

Proceedings overview

Zero AIA trial proceedings are on file against US 8,426,450. The USPTO ODP record shows 0 IPRs, 0 PGRs, and 0 CBM reviews (no breakdown by status is possible because there is nothing to break down), and my independent searches of PTAB docket mirrors surfaced no petition, institution decision, FWD, or appeal naming the '450 patent at any time since it issued on 2013-04-23. Defensive posture: this is not a hardened patent and not a canceled one — it is an untested patent. Nobody has ever run an AIA trial against it, so there is no claim-level validity ruling to leverage and, equally, no § 315(e)(2) estoppel attaches to anyone on the '450 patent. A defendant today faces a clean slate: full runway under § 311–§ 319, subject only to the one-year § 315(b) clock.

One important non-PTAB datum for posture-setting: the '450 patent is Orange-Book listed for NDA 210493 product 002 (fosnetupitant chloride HCl / palonosetron HCl, AKYNZEO IV) with Drug Substance and Drug Product codes and a listed use code — i.e., it is a substance patent, not merely a formulation patent (Orange Book printout for N210493, submitted as Ex. 2021 in IPR2025-00945: https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2025-00945/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/08-04-2025-Patent_Owner/Exhibit-2021-Exhibit_2021/). That makes it commercially the most consequential patent of the Akynzeo IV family — and the fact that it has never drawn a petition while sibling patents have drawn five is itself a strategic signal (see below).

A caution on what "no activity" does and does not cover. ODP's AIA-trial field would not capture ex parte reexamination or pre-AIA inter partes reexamination. I found no public evidence of either on the '450 patent, but I cannot certify their absence with the same confidence as the AIA-trial count. There is also a standing caveat that a petition filed very recently may not yet be indexed; nothing in my searches suggested one.

No proceedings to itemize

Because the canonical list is empty, there are no proceeding numbers, petitioner names, panels, institution decisions, FWDs, settlements, or § 315(e)(2) estoppel events to report for US 8,426,450. I will not manufacture any. What follows is the surrounding context that a defendant actually needs, clearly flagged as involving other patents, not the '450.

Context — IPR2025-00945 through IPR2025-00949 (Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.) — NOT the '450 patent

• Patents challenged: US 8,623,826 (the '826 patent, "Compositions and Methods for Treating Centrally Mediated Nausea and Vomiting") in IPR2025-00945; US 9,186,357 in IPR2025-00946 and IPR2025-00947; US 9,943,515 in IPR2025-00948; US 10,828,297 in IPR2025-00949.
• Filed: 2025-05-01 (all five, concurrently).
• Petitioner / RPI: Azurity Pharmaceuticals, Inc.; counsel Wilson Sonsini Goodrich & Rosati (Richard Torczon).
• Patent owner: Helsinn Healthcare S.A.; counsel Paul Hastings.
• Institution: In IPR2025-00945, institution granted 2025-11-19 as to claims 1–25 of the '826 patent; panel Fitzpatrick, Snedden (author), Paulraj. Notably, then-Acting Director Stewart denied Helsinn's request for discretionary denial on 2025-09-19 and referred the petition to the Board — Helsinn had argued, inter alia, that the '826 patent "has been in force for more than ten years, creating 'strong' settled expectations."
• Grounds (as instituted in -00945): § 103 only, over MASCC (2006) + Hoffmann (2006); MASCC + Bös (US 6,297,375); MASCC + Bös + ALOXI label; Herrstedt + Hoffmann + Hargreaves; Herrstedt + Bös + Hargreaves; Herrstedt + Bös + Hargreaves + Herrington; Herrstedt + Bös + Hargreaves + ALOXI.
• Live issue of note: Azurity's petitions attack Helsinn's Rule 132 evidence head-on, alleging the examiner was misled — that aprepitant data showing nausea benefit was withheld/altered and that "unexpected synergy" for netupitant + palonosetron is illusory.
• Defensive value to a '450 defendant: none directly — but this is the playbook to copy. Every reference in Azurity's grounds (Herrstedt, Bös = US 6,297,375, Hoffmann, Hargreaves, Herrington, MASCC, ALOXI label) is prior art to the '450 patent's 2011-11-29 priority date as well, and Azurity's institution on 2025-11-19 proves at least one PTAB panel found a reasonable likelihood of prevailing on materially similar § 103 theories across this family.

Context — litigation assertion of the '450 patent (not a PTAB matter)

• Helsinn Healthcare S.A. v. Gland Pharma Limited, D.N.J. Civil Action No. 22-cv-04635 (ZNQ)(LHG), filed on the basis of Gland's Paragraph IV notice regarding claims 1–3 of the '450 patent among other patents (amended answer: https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf).
• The case was resolved by a Consent Judgment and Dismissal Order in which Gland admitted the ANDA submission was a technical act of infringement under § 271(e)(2)(A) and stated it "has not rebutted the statutory presumption" of validity, expressly "without prejudice to Gland's defenses and counterclaims that the Helsinn Patents are invalid." No validity determination was ever made: https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf. (The copy I retrieved does not bear a legible entry date; I am not asserting one.)
• Read this for what it is: a settlement, not a validity win for Helsinn. Two defendants (Gland; and the earlier wave of '450-adjacent disputes) have now walked away from litigating '450 validity. Absence of an IPR on the '450 patent is not evidence the '450 patent is strong.

Strategic summary

Claim status: everything is UNTESTED. There is no claim of US 8,426,450 that has been canceled, and none that has been sustained by the PTAB — because no claim has ever been put at issue in an AIA trial. There are therefore no "surviving" claims to list and no "dead" claims to avoid asserting against. Any statement to the contrary (e.g., "claims 1–5 were canceled") would be false as to this patent. Note also that I could not verify the full issued claim set of the '450 patent from the sources I retrieved; the only claim numbers I saw tied to '450 in a public record are claims 1–3, from the Gland Paragraph IV notice as recited in Helsinn's complaint. Do not assume the claim count from the published application family.

Estoppel landscape: wide open. Because no IPR/PGR/CBM ever reached a final written decision on the '450 patent, no petitioner (or privy) is barred under 35 U.S.C. § 315(e)(2) from raising any § 102/§ 103 ground in district court on this patent. There is also no § 325(e)(2) estoppel. A defendant filing a first IPR against '450 faces no § 315(b) problem unless it was served with a complaint alleging infringement of '450 more than one year ago — so check the service date first; that is the one clock that matters here. Because '450 issued 2013-04-23 and reissue/PGR windows are long closed, IPR under § 311 is the only AIA vehicle (PGR is unavailable; CBM is not applicable to a pharmaceutical compound patent). Two genuinely available avenues exist as alternatives or complements: ex parte reexamination (no estoppel, no participation) and, if the target is an Orange-Book-listed substance claim, a § 271(e)(2) declaratory posture in the ANDA litigation itself.

Pattern signals. (1) No serial-petitioner history on '450 at all — Azurity's five-petition salvo targets the '826, '357, '515 and '297 patents, not '450. (2) Azurity is a commercial rival with its own antiemetic program (it holds a tentative approval for an aprepitant injectable emulsion, discussed in its petitions), not a defensive aggregator; Unified Patents appears nowhere in this chain. (3) Helsinn fights discretionary denial hard (see its briefs in IPR2025-00945) and is plainly prepared to litigate on the merits. (4) The patent family is deep and continuations run to 2020+, so a defendant attacking '450 should expect Helsinn to pivot to the children — notably US 9,403,772, 9,908,907, 10,208,073, 10,717,721 and 11,312,698, all of which claim priority through the '450 via the PCT/US2012/066778 chain and are subject to terminal disclaimers.

Recommended next steps

1. Treat the '450 patent as untested but challengeable, not as hardened. There is no FWD to cite and no canceled claim to quote. If opposing counsel suggests the patent is "PTAB-hardened," that is unsupported: it has simply never been tested.
2. Pull the '450 claim set and prosecution history before anything else. I could not verify it here; the specific claims you must map are the ones recited in the issued patent, and the specification's own admissions are unusually helpful § 103 ammunition: it states that US 5,985,856 (Stella, University of Kansas — N‑phosphoryloxymethyl derivatives of tertiary amines) "does not disclose how the N‑phosphoryloxymethyl moiety would affect other critical attributes of the drug product, such as stability, local tolerance at the site of administration, bioavailability, metabolism or toxicity," and that US 6,747,026 (Hoffmann‑La Roche — mono‑N‑oxide derivatives of 4-phenyl-pyridines) reports "no physicochemical or biological data of the mono-N-Oxide derivatives." If the '450 claims are directed to the GA1–GA8 species (fosnetupitant and the N-oxide derivatives), those two patents are the obvious § 102/§ 103 anchors and the specification has conceded the gaps.
3. File early on the § 315(b) clock. Compute one year from the earliest service of a complaint alleging infringement of the '450 patent on your client or its privies. Once barred, you are confined to § 282 defenses in court.
4. Reuse Azurity's record; avoid its estoppel. Azurity's grounds, exhibits and expert declaration are public and free to cite, and — because Azurity never petitioned against '450 — there is no privity/estoppel risk in copying its theory as applied to the '450 patent. But note the counter-lesson from IPR2025-00945: the Board rejected Helsinn's ten-year "settled expectations" discretionary-denial argument, which weakens any similar argument Helsinn might raise against a new '450 petition.
5. Monitor the parallel trials for claim-construction and Rule 132 spillover. IPR2025-00945 (instituted 2025-11-19) has an FWD due within one year of institution — i.e., on or about 2026-11-19 under the § 316(a)(11) clock. If the Board finds the netupitant/palonosetron synergy evidence insufficient there, that reasoning is directly transferable to any '450 attack that relies on the same specification.
6. Do not overlook non-AIA options. Confirm there has been no ex parte or inter partes reexamination of '450 (the ODP AIA-trial block would not show one) before finalizing a challenge strategy.

Primary links

• Corresponding IPR docket for the flagship sibling proceeding: https://www.docketalarm.com/cases/PTAB/IPR2025-00945/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/
• Institution decision, IPR2025-00945 (2025-11-19): https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2025-00945/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/11-19-2025-Board/Institution_Decision__Grant-12-Institution_Decision__Granting_Institution_of_Inter_Partes_Review_35_USC_sec_314/
• Gland Consent Judgment (D.N.J. 22-cv-04635), resolving the '450 assertion: https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf
• Gland's answer/counterclaims referencing claims 1–3 of the '450 patent: https://storage.courtlistener.com/recap/gov.uscourts.njd.499051/gov.uscourts.njd.499051.25.0.pdf
• USPTO PTAB decisions portal (for verifying no '450 FWDs): https://www.uspto.gov/patents/ptab/decisions
• CourtListener (for any Federal Circuit appeal naming US 8,426,450): https://www.courtlistener.com/?q=%228426450%22

Confidence statement

High confidence: no AIA trial proceeding has ever been instituted or decided on US 8,426,450, per the ODP structured block and corroborating searches. High confidence: the Azurity IPR2025-00945–00949 cluster challenges other Helsinn patents, not '450. Lower confidence (unverified here): the '450 patent's exact claim count and claim scope; the entry date of the Gland consent judgment; and the complete absence of reexamination history. Any of those should be verified directly on PatentCenter/PTAB E2E before being relied on in a filing.

I'll start by gathering what authoritative sources show about this patent's ownership record, then verify specifics.

Let me verify the secured-party entity and check for the correspondent/reel details.

US 8,426,450 B1 — "Substituted 4-phenyl pyridines having anti-emetic effect"

Methodological caveat up front: I worked from the Google Patents legal-events feed for this patent (https://patents.google.com/patent/US8426450/en), USPTO/PTAB and district-court filings surfaced via search, and secondary databases (DrugPatentWatch, Unified Patents portal, IPWatchdog). The Assignment Center UI (https://assignmentcenter.uspto.gov/) is not queryable from my tooling, and Google Patents does not expose reel/frame numbers. So unlike the template request, I cannot give you verified reel/frame citations, and I will not invent them. Everything below is anchored to recordable dates, named parties, and conveyances; where a reel/frame would normally go, I flag "reel/frame not retrievable."

Inventors

Named on the face of the patent (8 inventors):

Patterns worth noting:

• This is a normal corporate inventorship group. All but Stella appear to be Helsinn employees; Stella is an outside academic collaborator contributing the prodrug chemistry. There is no evidence of inventors departing within 12 months of filing — the standard "portfolio fire-sale" precursor is absent. Several of these inventors (Fadini, Manini, Pietra, Giuliano, Lovati, Cannella, Venturini) recur across the later Helsinn continuation family (e.g. US 9,403,772; US 9,908,907), which is a hallmark of a stable in-house R&D team, not a one-shot shell filing.
• ⚠️ Anomaly in the assignment record: the recorded assignment lists a ninth assignor, Riccardo Braglia, who is not a named inventor on the '450 patent. Braglia is the Helsinn group's principal (Braglia family holding). This is most consistent with a bundled multi-application assignment naming a company officer/rightsholder, but I cannot confirm the reason. Flagging as an unexplained discrepancy, low confidence.

Original assignee

Helsinn Healthcare SA — privately held, family-owned Swiss pharmaceutical company, registered in Lugano-Pazzallo, Switzerland. Named original assignee on the issued patent and still the assignee of record today.

• Primary line of business: specialty pharma, B2B licensing + in-licensed late-stage assets developed to market (per the Helsinn v. Dr. Reddy's trial record: no internal sales force or formulation labs historically; used CROs/CMOs).
• Does it ship a product embodying the claims? Yes. US 8,426,450 is listed in the FDA Orange Book (par. DS, DP, expiry 2023-05-23 per FDA and 2032-05-23 with term) for Akynzeo® (NDA 210493), the fosnetupitant chloride HCl / palonosetron HCl IV product commercialised by Helsinn. The '450 claims cover fosnetupitant (GA1 in the specification is the compound that became fosnetupitant). Helsinn itself pleaded in D.N.J. that it "manufactures and sells fosnetupitant chloride hydrochloride palonosetron hydrochloride drug products for intravenous infusion under the brand name Akynzeo®."
• Current status: operating. Not in bankruptcy, not acquired, not dissolved. Subsidiaries in the chain: Helsinn Birex Pharmaceuticals Limited (Irish manufacturing) and Helsinn Therapeutics (U.S.), Inc. (US commercial). A 2022 security interest and 2023 release (below) indicate secured financing, not distress.

Assignment timeline

Three recorded events. No assignment ever transferred title away from Helsinn Healthcare SA.

• 2012-11-28 (recorded; executed on or about the 2012-05-23 filing) — Reel/frame not retrievable

  • Conveyance: Assignment (inventor-to-corporation)
  • Assignor: Luca Fadini; Peter Manini; Riccardo Braglia; Roberta Cannella; Claudio Giuliano; Emanuela Lovati; Claudio Pietra; Alessio Venturini; Valentino J. Stella
  • Assignee: Helsinn Healthcare SA
  • Correspondent: not retrievable — Google Patents legal events do not carry the recording correspondent, and I could not reach the Assignment Center record. No correspondent can be reported honestly here.
  • Context: Ordinary employee/inventor assignment perfecting title in the operating parent. (Note: recorded seven days after the US'361 filing date but predating issuance.)

• 2022-12-30 (recorded) — Reel/frame not retrievable

  • Conveyance: Security Interest (Security Agreement — conveys a lien, not title)
  • Assignor: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Assignee/Secured party: Hamilton SA LLC
  • Correspondent: not retrievable
  • Context: Securitization — collateral grant over the Helsinn group's IP (including the '450 patent) to a security agent, i.e. secured lending, consistent with a group-level credit facility. This is the opposite of an NPE transfer: a lender perfecting a lien. Note the timing — recorded seven days after the Gland consent judgment (2022-12-23), i.e. tied to a corporate financing event, not to litigation.

• 2023-09-20 (recorded) — Reel/frame not retrievable

  • Conveyance: Release by Secured Party (termination of the 2022 security interest)
  • Assignor: Hamilton SA LLC
  • Assignee/Releasee: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Correspondent: not retrievable
  • Context: Release / lien discharge — the secured party released the encumbrance, leaving Helsinn Healthcare SA as unencumbered title holder. Chain terminates at the original innovator.

(No merger, change-of-name, licence, or correction records appeared for this patent.)

Timeline diagram

timeline
    title Ownership of US 8426450
    2011 : Priority application filed
    2012 : US application filed
         : Inventors assign to Helsinn Healthcare SA
    2013 : Patent issues as US 8426450
    2022 : Helsinn sues Gland Pharma in New Jersey
         : Security interest granted to Hamilton SA LLC
    2023 : Hamilton SA LLC releases security interest

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. The only non-Helsinn entity in the chain is Hamilton SA LLC, and its recorded role on 2022-12-30 is expressly a Security Interest, discharged on 2023-09-20 by a Release by Secured Party. No "IP / Licensing / Holdings / Ventures" entity ever appears, and no title ever left Helsinn Healthcare SA.

2. Known asserter in the chain — Not present. No assignee or assignor matches Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, or any Spangenberg-affiliated entity. Unified Patents classifies the plaintiff in 3:22-cv-04635 as "Operating Company — Medical."

3. Repeat correspondent across the chain — Unclear / not determinable. I could not retrieve the recording correspondent for any of the three events, so I cannot test for recurrence. This is a data-access gap, not a negative finding — do not read "unclear" as exculpatory.

4. Cascading transfers — Not present. Three recorded events span roughly eleven years (2012 → 2023), and two of the three are a matched lien grant and lien release. There is no chain of LLCs and no clustering inside 24 months.

5. Pre-litigation transfer — Not present. Helsinn Healthcare SA was assignee of record both before and after filing of 3:22-cv-04635 on 2022-07-18; no title transfer preceded suit. The 2022-12-30 security interest is post-litigation and is a lien, not a transfer of standing.

6. Bankruptcy fire-sale — Not present. No Chapter 7/11 proceeding for Helsinn Healthcare SA or its subsidiaries appears; the group remains an operating, family-owned business funding its own enforcement.

7. Privateering — Not present. Helsinn sues its own ANDA competitors (Gland Pharma; earlier Teva and Dr. Reddy's) to protect its own marketed product, Akynzeo®. There is no NPE asserting on Helsinn's behalf — Helsinn litigates in its own name through Paul Hastings / Saul Ewing and defends the patents in its own name in IPR2025-00945/946/948/949 against Azurity.

8. Defensive aggregator (anti-NPE) — Not present. Chain does not terminate at RPX, AST, LOT, Unified Patents or OIN.

Verdict

Operating-company assertion.

Justification: Helsinn Healthcare SA has been the sole titleholder of record throughout — the 2012-11-28 inventor assignment conveyed the '450 patent to Helsinn and no subsequent record ever moved title off it. The only later events are a security interest granted to Hamilton SA LLC on 2022-12-30 and its release on 2023-09-20, which are secured-financing mechanics, not an NPE acquisition. Helsinn ships Akynzeo® (the Orange Book-listed product practising the '450 claims) and asserted this patent in its own name against a generic ANDA filer in Helsinn Healthcare S.A. v. Gland Pharma Ltd., 3:22-cv-04635 (D.N.J., filed 2022-07-18, terminated 2022-12-23 by consent judgment) — classic operating-company-versus-competitor enforcement.

Verify (I could not): Assignment Center search for patent 8,426,450 — https://assignmentcenter.uspto.gov/ (reel/frame and recording correspondent for the three events above should be pulled directly there and reconciled against this chain).

I'll research the prior-art citations for US 8,426,450 specifically. Let me pull the patent's citation records and related references.

I have the citation list. Now let me get details on each cited reference to build full citations and descriptions.

Prior Art Analysis — US 8,426,450 B1 ("Substituted 4-phenyl pyridines having anti-emetic effect")

Scope, method, and an important limitation

You asked me to "search the USPTO database" for 8426450 and analyze each of its patent citations. Two caveats up front:

1. Identifier discipline. I interpreted everything literally. US 8,426,450 B1 = application 13/478,361, filed 2012-05-23, granted 2013-04-23, priority US 61/564,537 (2011-11-29), assignee Helsinn Healthcare SA. I did not retrieve or substitute any other number (e.g., not 6,426,450, 8,426,540, etc.).
2. Source limitation. I do not have authenticated direct access to USPTO PatentCenter/Global Dossier in this session. The authoritative full patent text you supplied does not itself include the "References Cited" section (the fetched HTML carried the description/claims but not the front-page citation list). The citation list below therefore comes from the aggregators that mirror the printed face of the patent (FreePatentsOnline, PubChem/NCBI, Google Patents). Where a date or claim mapping is not confirmed to high confidence, I say so.

Critical gap flagged: I could not retrieve the verbatim issued claim language of US 8,426,450. The FreePatentsOnline record shows claim numbering (1., 2., 3. …) but the claim text rendered blank; the WO 2017/211663 search report lists US 8,426,450 as relevant to claims 1–20 and cites claim 1 plus columns 17–21 and 39–41. So the mapping of a reference to "which claim it anticipates" below is a reasoned mapping to the claim types (compound genus / species / composition / method), not a verified element-by-element claim chart. Treat the specific claim numbers as subject to verification against the printed patent.

A. The face-of-patent US patent references (the "patent citations" for '450)

These are the ten U.S. patents listed under "US Patent References" on the '450 record. All predate the '450 priority date (2011-11-29) and the pre-AIA filing date (2012-05-23), so pre-AIA 35 U.S.C. § 102 governs.

Non-patent literature references listed on the '450 record

(PubChem's citation list for US-8426450-B1 matches this set exactly: it enumerates US-5985856, 6297375, 6303790, 6479483, 6531597, 6593472, 6719996, 6747026, 6806370, 7211579, plus the two NPL items — 12 citations total.)

B. The three references the patent itself identifies as most relevant

The '450 specification's Background section singles out exactly three pieces of prior art — the strongest signal of relevance:

• US 6,297,375 (Bös / Roche) — described as disclosing "a class of 4-phenyl-pyridine compounds that are NK1 antagonists … Netupitant is a selective NK1 receptor antagonist among these 4-phenyl-pyridine compounds."
• US 6,747,026 (Hoffmann / Roche) — described as disclosing "Mono-N-Oxide derivatives of 4-phenyl-pyridine compounds," intended to improve solubility/PK, but with "no physicochemical or biological data."
• US 5,985,856 (Stella / Kansas) — described as disclosing "water soluble N-phosphoryloxymethyl derivatives of secondary and tertiary amines … to improve the solubility profiles of loxapine and cinnarizine," but "does not disclosure how the N-phosphoryloxymethyl moiety would affect other critical attributes … stability, local tolerance …, bioavailability, metabolism or toxicity."

The inventors then frame the invention as meeting this unmet need. That framing is essentially an admission that these three references are the closest prior art — and, if the issued claims had read on the subject matter of any of them, they would have anticipated. The fact that the patent issued implies the issued compound claim 1 is narrower than the bare netupitant/4-phenyl-pyridine scaffold and narrower than the '026 mono-N-oxide genus as such.

C. § 102 anticipation analysis (claim-type mapping)

Because the verbatim claims are unverified, I map each reference to the classes of claims the '450 family is known to contain — (i) a compound/Markush genus, (ii) species/compound-specific claims, (iii) pharmaceutical-composition claims, and (iv) method-of-treating claims — and state where each reference could anticipate.

1. US 6,297,375 (Bös; netupitant) — strongest § 102(a)/(b) reference for the compound claims.
This patent discloses and claims netupitant itself (Ex. 14; claim 16) and a broad genus of 4-phenyl-pyridines with an amide linker and a cyclic tertiary amine (piperazinyl, morpholinyl, etc.). If any issued claim of '450 covers unmodified netupitant (or the unmodified 4-phenyl-pyridine scaffold), § 102(a)/(b) is squarely met. If the issued claims are limited to the modified derivatives (N-oxide, N-phosphoryloxymethyl, N-acyloxymethyl), then '375 anticipates only claims that read on the unmodified base and otherwise serves as the § 103 starting point.

2. US 6,747,026 / 6,593,472 / 6,806,370 (Hoffmann; amine-oxide prodrugs) — § 102(a)/(b) for the N-oxide claims.
These are three members of one Roche family (priority 2000-07-14; WO 02/06236) claiming N-oxides of 4-phenyl-pyridine NK-1 antagonists as prodrugs, including the morpholine-N-oxide species (US 6,747,026 claims 4–7). They potentially anticipate any '450 claim covering the mono-/di-N-oxide compounds GA4–GA8. But note the internal contradiction in the '450 specification: formula (I)'s Z includes an N-oxide (formula Ia), yet another embodiment "excludes all N-oxide forms," and the genus carries a proviso that if a non-pyridine N-oxide is present then total N-oxides must be > 1 (see §D below). This inconsistency materially affects whether the N-oxide references anticipate the compound claims as issued.

3. US 5,985,856 (Stella; N-phosphoryloxymethyl prodrug platform) — § 102 versus § 103.
This reference discloses the generic N-phosphoryloxymethyl quaternary-ammonium prodrug structure — it does not disclose a 4-phenyl-pyridine species. Anticipation requires that a single reference disclose every element of the claim; a platform genus lacking the specific 4-phenyl-pyridine would typically support an obviousness (§ 103) rejection rather than § 102, unless a claim of '450 is drafted so broadly that the '856 genus alone reads on it. (Also note: Valentino J. Stella is a named co-inventor on '450 and a named inventor on '856 — a potential § 102(a)/(b)/§ 103 "inventor's own work" nuance that does not, by itself, remove '856 as prior art under pre-AIA § 102(b).)

• '450's GA1 (fosnetupitant) and GA2/GA3 (the acetoxymethyl / butyryloxymethyl quaternary ammoniums) are the most plausible targets; expect these to be § 103 rather than § 102 references.

4. US 6,479,483 (Bös; 4-phenyl-pyridines) and US 7,211,579 (Funk; NK-1 antagonists) — § 102(a)/(b)/(e) for genus-type claims; otherwise § 103.
Both are additional NK-1 antagonist genus disclosures. If claim 1 of '450 is a broad genus that arguably overlaps them, these are anticipatory; if claim 1 is limited to the specific modified derivatives, they are secondary § 103 art.

5. US 6,303,790 and US 6,531,597 (process patents) and US 6,719,996 (galenic composition) — § 103, not § 102.
Process and formulation disclosures do not disclose the claimed compounds; they are relevant to any process or composition claims and to obviousness of making/formulating, not to anticipation of compound claims.

6. Kramer et al. (1998) and Gesztesi et al. (2000) — § 103/background only.
These disclose the therapeutic use of NK1 antagonists in emesis/depression; they do not disclose the '450 compounds. They are background for method-of-treatment and combination claims (including the palonosetron/dexamethasone regimens described in the '450).

D. Contradictions and flags

1. Claim-text gap (already noted): the issued claims of '450 could not be retrieved verbatim in this session. The clause "which claim it anticipates" is answered by claim type, not verified claim number. The WO 2017/211663 search report corroborates claims 1–20 and cites claim 1.
2. N-oxide inconsistency inside the '450 specification: formula (I) expressly includes N-oxide Z-groups (formula Ia), the genus carries a proviso requiring > 1 N-oxide in certain cases, and yet another embodiment "excludes all N-oxide forms." This directly affects the § 102 weight of the Roche amine-oxide references (US 6,593,472 / 6,747,026 / 6,806,370).
3. Overlap between sub-numbers (interpreted literally): US 6,593,472; 6,747,026; and 6,806,370 are all titled "NK-1 receptor active amine oxide prodrugs" with the same Hoffmann et al. inventorship and priority (2000-07-14) — they are the same family, not independent art. US 6,297,375 and US 6,479,483 are both "4-phenyl-pyridine derivatives" (Bös et al.), again a related Roche grouping. Treat these as families, not as distinct prior-art dates.
4. The reference list I used is aggregator-derived, not the printed patent's own "References Cited." The authoritative full text you supplied omits that section. I could not verify a separate foreign patent reference list for '450 (FPO showed none, unlike US 6,297,375, which lists many foreign/WO items). This should be checked against the printed patent.
5. Date discrepancy in the prompts: the system clock reads 2026-09-19 while this task states April 26, 2026; and the previously generated material states April 26, 2026. This affects only framing, not the prior-art facts.

E. Forward citations to US 8,426,450 (for completeness)

Several later documents cite '450 (i.e., it is prior art to them), which is the mirror-image of your question: CN 104053652 A / CN 106518924 A / CN 106986822 B (Helsinn family filings), WO 2017/211663 A1 (search report cites '450 as category "A" against claims 1–20), MY 194081 A (lists US 8426450 B1 among prior art), RU 2681316 C2 (lists US 8426450 as "patent literature 18"), and US 12,097,197 B2 (Slayback Pharma; lists 8,426,450 under "Referenced Cited"). These are not § 102 art against '450; they confirm only that '450 is itself a widely-cited reference.

Bottom line

• Most relevant prior art to US 8,426,450: (1) US 6,297,375 (Bös/Roche — discloses netupitant and the base 4-phenyl-pyridine genus → potential § 102(a)/(b) anticipation of compound claims reading on the unmodified scaffold); (2) US 6,747,026 (and its family members 6,593,472 / 6,806,370) — Hoffmann/Roche amine-oxide prodrugs → potential § 102(a)/(b) anticipation of N-oxide claims; (3) US 5,985,856 (Stella/Kansas) — N-phosphoryloxymethyl prodrug platform → primarily a § 103 reference against the GA1-type claims.
• Secondary: US 6,479,483, US 7,211,579 (genus/§ 102–103), US 6,303,790 and US 6,531,597 and US 6,719,996 (process/formulation/§ 103), and the two NPL items (Kramer 1998; Gesztesi 2000) as background/§ 103 support.
• Unresolved: the exact issued claim language of '450 — without it, no element-by-element § 102 anticipation chart can be certified.

I'll research the prior-art references identified in the patent's own Prior Art section and the Gland counterclaim, then build the §103 analysis.

Let me nail down the remaining references from the prior-art section and the Gland counterclaim.

Obviousness Analysis — U.S. Patent No. 8,426,450 under 35 U.S.C. § 103

Analyst note on method. This analysis builds on the summary and litigation sections already generated. It uses the references that appear in the "Description of Related Art" / Prior Art section of the '450 patent itself (the five items the patent cites), supplemented by the art the Gland Pharma counterclaim pleaded against the '450 (which is the closest thing to a real-world §103 challenge on record). Two caveats carried forward: (1) I still could not retrieve the verbatim issued claim text of the '450, so claim 1 is treated as the compound genus of formula (I) with GA1–GA8 as species and with composition/method independent claims, per the prior section; (2) the '450 text prints "Kramer et al., Science 281(5383), 1640‑1645, 1988," while the Bös patents cite the same article as 1998. I interpret the identifier literally as printed in the '450 but flag the date inconsistency.

1. The five prior-art items in the '450's own Prior Art section

Also on the page: the "Prior Art keywords" list — compounds, phenyl, group, solution, ring — confirms the examiner/Google indexing treated the art as directed to (a) the phenyl/pyridine genus and (b) solution/solubility.

Supplementing PA‑1–PA‑5 from the counterclaim record (Bös, WO 99/33846, Krise I, Oslob, DeGoey, Funk — see the litigation section): Krise I (J. Med. Chem. 1999, 42, 3094‑3100, https://pubs.acs.org/doi/10.1021/jm980539w) and WO 99/33846 are the same Stella/Kansas POM invention as PA‑5, and Bös (U.S. 6,479,483 / 6,297,375) is the same netupitant-disclosing genus as PA‑3. The counterclaim therefore evidences that a skilled challenger saw the '450 as an addition of known prodrug chemistry onto a known compound.

1.1 Level of ordinary skill (Graham factor 1)

A PHOSITA here is a medicinal chemist/pharmaceutical scientist (Ph.D. or M.S. + several years) with experience in (i) NK1‑antagonist 4‑phenyl‑pyridine chemistry and (ii) prodrug/soft‑drug design for parenteral formulation of poorly soluble amine drugs. Both PA‑4 and PA‑5 are directed to exactly that second skill; PA‑3 to the first.

2. The differences between the prior art and the claims (Graham factor 2)

The '450 adds nothing but two known bioreversible derivatizations of a known tertiary amine, applied to a known drug:

• N‑oxidation of the 4‑phenyl‑pyridine (PA‑4) → GA4–GA8 and the "oxide" Z variants of formula (I).
• N‑phosphoryloxymethyl quaternization (and its acyloxymethyl analogs) of the piperazine nitrogen (PA‑5) → GA1 (= fosnetupitant) and GA2/GA3.

The '450's own Background concedes the motivation by stating: "there is a need to find new derivatives of 4‑phenyl‑pyridine compounds that are effective NK1 receptor antagonists, with enhanced physicochemical and/or biological properties." That is the stated problem, and PA‑4 and PA‑5 each supply the known solution.

3. Combination grounds

Ground A — The N‑oxide species/subgenus: PA‑3 (netupitant) + PA‑4

Combination: PA‑3/U.S. 6,479,483 discloses netupitant, a 4‑phenyl‑pyridine bearing a cyclic tertiary amine (4‑methylpiperazin‑1‑yl). PA‑4 discloses that N‑oxidizing that very class of ring nitrogen yields NK1‑active prodrugs with improved solubility and bolus‑injectability, and its genus expressly names piperazinyl among the cyclic tertiary amines and its examples place the N‑oxide on the o‑tolyl‑pyridin‑3‑yl‑amide core.

Motivation / reasonable expectation (KSR): PA‑4 is not merely analogous art — it is the same scaffold (4‑phenyl‑pyridine), the same target (NK1), and the same purpose (solubility/PK for injection). KSR ("a technique used to improve one device … would improve similar devices in the same way") and the "obvious to try" line both apply. A PHOSITA would expect the piperazine N‑oxide of netupitant (GA8) — and its pyridine‑N‑oxide and di‑N‑oxide homologs (GA5, GA6, GA7, GA4) — to be NK1‑active prodrugs, because the N‑oxide is cleaved/active by the same mechanism PA‑4 reports for its own species.

Note on the proviso: the '450's "if a non‑pyridine N‑oxide is present, then the total number of N‑oxides must be more than one" limitation is a negative limitation that does not confer patentability — it merely carves out the mono‑piperazine N‑oxide, i.e., it concedes that the single non‑pyridine N‑oxide (the PA‑4 strategy) was already known/obvious, and claims only the multi‑N‑oxide permutations (pyridine‑N‑oxide + piperazine‑N‑oxide, piperazine‑1,4‑dioxide). Multiplying known oxidation sites is routine. ⚠️ This proviso also sits in tension with the '450 embodiment that "excludes all N‑oxide forms," and with the prior summary's observation that the proviso and exclusionary embodiment coexist. If the issued independent claim reads on the non‑N‑oxide species only, Ground A collapses into Ground B for claim 1; if it retains the N‑oxide subgenus, Ground A applies. This is exactly why the verbatim claim text matters and I cannot fully resolve it.

Ground B — GA1 (fosnetupitant) and the POM subgenus: PA‑3 + PA‑5

Combination: Netupitant (PA‑3) contains a tertiary amine (the 4‑methylpiperazine). PA‑5 claims/discloses N‑phosphoryloxymethyl prodrugs of tertiary‑amine drugs generically — the claim language is deliberately drug‑agnostic ("substituents which comprise the parent tertiary amine"), the express object is increased aqueous solubility with reduced toxic side effects at physiological pH without cosolvent, and the express contemplated route is intravenous/parenteral.

Element‑by‑element: GA1 = 4‑(netupitant‑5‑yl)‑1‑methyl‑1‑((phosphonooxy)methyl)piperazin‑1‑ium. That is precisely the structure PA‑5's Formula VI/VIa produces when R¹R²R³ = the netupitant piperazine. PA‑5 even contemplates the internal salt (quaternary N⁺ balanced against the phosphate anion) — matching the zwitterionic nature of GA1.

Motivation: (i) Netupitant is a poorly soluble base whose marketed route required an IV option; (ii) PA‑4 (same patent family, cited in the '450) establishes that the problem to be solved is delivery of this scaffold parenterally; (iii) PA‑5 supplies a known, general, structure‑independent solution; (iv) Krise I / WO 99/33846 (same invention, Gland‑cited) show rapid, quantitative in‑vivo reversion to the parent amine in dogs — i.e., a reasonable expectation of success that does not depend on the identity of the amine drug. There is no teaching away: PA‑5's background expressly laments that the tertiary‑amine functional group "has received little if any attention," which is an invitation, not a deterrent.

Ground C — The salts/adducts and dosage limitations: PA‑5 + routine formulation

PA‑5 recites pharmaceutically acceptable cations/anions, lyophilized forms, pH 4.5–9.5, concentrations 0.1–1000 mg/ml for IV delivery. The '450's claimed IV dosage (1–20 mg/ml, ~10 mg/ml) and salt/adduct language are routine optimization of PA‑5's disclosed ranges → KSR "design incentives" and In re Aller/"results‑effective‑to‑optimize" reasoning.

Ground D — GA2/GA3 (acetoxymethyl / butyryloxymethyl): PA‑5 + known labile‑quaternary‑ammonium art

PA‑5's own Background recites the Bodor labile quaternary ammonium salts (Formula I: R,R¹ = H/alkyl/aryl; X = O or S; Y = halogen) and Bogardus labile quaternary ammonium derivatives, and the '450's search surfaced Davidsen, N‑(acyloxyalkyl)pyridinium salts as soluble prodrugs, and Nielsen (N‑acyloxymethyl quaternary derivatives of tertiary amines). GA2/GA3 are the netupitant analogs in which the POM phosphate is replaced by an acyloxymethyl promoiety (acetate/butyrate). Selecting among known bioreversible quaternary‑ammonium promoties (phosphate vs. acyloxy) on the same drug is a predictable variation with an expected result (a soluble quaternary salt that reverts to netupitant). KSR: "when a patent … simply arranges old elements with each performing the same function it had been known to perform."

Ground E — The full genus (formula (I)): PA‑3 + PA‑4 + PA‑5

The genus is a Markush union of two known derivatizations (Z = "oxide" from PA‑4; Z/X quaternary‑ammonium/phosphoryloxymethyl variants from PA‑5) on the known netupitant scaffold (PA‑3). Where a genus is the obvious structural union of two references each teaching one branch for the same purpose on the same/similar core, §103 forecloses the genus. The '450 offers no data showing members outside the specifically exemplified GA1–GA8 have unexpected properties — the rat/dog PK section compares only compound 1 (fosnetupitant) and netupitant.

Ground F — The method‑of‑treatment / composition claims: PA‑1 + PA‑2 + PA‑3

Once the compound genus is obvious, the composition and method‑of‑treating‑NK1‑mediated‑disease claims add only the known utility: PA‑1 (Kramer) and PA‑2 (Gesztesi) establish emesis as a known NK1 indication, and PA‑3/PA‑4/PA‑5 all recite the antiemetic/CNS utility. A method of using an obvious compound for its known and disclosed utility is obvious (In re Kuehl; In re Spada‑type reasoning). The specification's "preferred regimen" (PALO + dexamethasone) tracks already‑public antiemetic combinations (Herrstedt; Aloxi per the CN/EP family members surfaced) and the '450's own dosing ranges are routine.

4. Secondary considerations — the counter‑case (Graham factor 4), and its limits

The strongest non‑obviousness argument for the '450 is that the '450 itself distinguishes PA‑4 and PA‑5 as silent on the attributes that actually mattered:

• Against PA‑4: "no physicochemical or biological data of the mono‑N‑oxide derivatives are reported in the '026 patent."
• Against PA‑5: "The '856 patent does not disclose how the N‑phosphoryloxymethyl moiety would affect other critical attributes … such as stability, local tolerance at the site of administration, bioavailability, metabolism or toxicity."

A patentee would frame this as unexpected results / non‑obvious property selection: the POM derivative of netupitant specifically might not have been predictable to be stable, non‑toxic at the injection site, and quantitatively converted — properties PA‑5 established only for loxapine/cinnarizine. Helsinn made essentially this unexpected‑results argument in the parallel netupitant‑'297 proceedings (Trento/Helsinn Rule‑132 and IPR record), asserting unexpected synergy/PK behavior. However:

1. PA‑5 already teaches the general class is water‑soluble, stable at physiological pH without cosolvent, alkaline‑phosphatase‑cleaved, and reverts to parent in dogs — so a PHOSITA would have a reasonable expectation, which is all §103 requires.
2. The '450's PK data appear to show conversion and PK comparability, not an order‑of‑magnitude or otherwise unexpected property. Data showing "it works as PA‑5 predicts" is not unexpected results.
3. Local tolerance/toxicity is a formulation‑optimization concern and is a classic routine‑testing argument that courts often discount absent comparative data vs. the closest prior art.
4. Any commercial success of Akynzeo‑IV would need a nexus to the specifically claimed POM species; a strong nexus argument is available for GA1 but weaker for the broad genus.

Net: secondary considerations could rebut the prima facie case for the narrow GA1 claim if the patentee produces credible comparative data against netupitant/POM‑on‑other‑drugs, but they are unlikely to rescue the broad genus or the N‑oxide subgenus.

5. Bottom line

Key limitation on this opinion: because I could not obtain the issued claim language, I cannot tell whether claim 1 is (a) the full formula‑(I) genus, (b) a narrower N‑oxide subgenus, or (c) a closed list of GA1–GA8. Ground A/B/E map cleanly onto (a)–(c) respectively, and the proviso/exclusion tension in the specification makes the precise scope dispositive. That should be verified against the printed '450 (USPTO PatentCenter) before this opinion is relied on. Likewise, the Kramer "1988" date as printed in the '450 appears to be a typo for 1998 (as cited in U.S. 6,479,483), which would matter only if a reference‑date (pre‑AIA §102) challenge turns on it.